Previous studies have demonstrated an increased risk of cutaneous melanoma (CM) after lymphoid neoplasms (LNs), such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). 1,2 Now, a ...

Patients with a history of cutaneous melanoma are at increased risk of developing lymphoid neoplasms and vice versa. This study found that these risks differ by subtype of lymphoid neoplasm and that ...

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, capture-based, next-generation ...

This is a preview. Log in through your library . Abstract A multi-centre hospital-based case-control study was conducted in three regions of France between 2000 and 2003 in order to establish the risk ...

The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...

Philadelphia, July 29, 2021 – Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, ...

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...

Ultra-low-pass whole genome sequencing (ULP-WGS) of circulating tumor DNA appears to provide important prognostic information regarding patients with large B-cell lymphoma (LBCL), according to ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...